101 related articles for article (PubMed ID: 15148575)
1. HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.
Ellerhorst JA; Hildebrand WH; Cavett JW; Fernandez-Vina MA; Hodges S; Poindexter N; Fischer H; Grimm EA
Urologe A; 2004 Sep; 43 Suppl 3():S137. PubMed ID: 15148575
[No Abstract] [Full Text] [Related]
2. Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy.
Ellerhorst JA; Hildebrand WH; Cavett JW; Fernandez-Vina MA; Hodges S; Poindexter N; Fischer H; Grimm EA
J Urol; 2003 Jun; 169(6):2084-8. PubMed ID: 12771724
[TBL] [Abstract][Full Text] [Related]
3. HLA class I and II antigens expression in patients with renal cell carcinoma.
Ozgur BC; Gonenc F; Yazicioglu AH
Saudi J Kidney Dis Transpl; 2009 Jan; 20(1):97-101. PubMed ID: 19112225
[TBL] [Abstract][Full Text] [Related]
4. Characterization of HLA-G expression in renal cell carcinoma.
Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
[TBL] [Abstract][Full Text] [Related]
5. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population.
Obara W; Suzuki Y; Kato K; Tanji S; Konda R; Fujioka T
Int J Urol; 2007 Jun; 14(6):483-7. PubMed ID: 17593089
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma.
Kleinrath T; Gassner C; Lackner P; Thurnher M; Ramoner R
J Clin Oncol; 2007 Mar; 25(7):845-51. PubMed ID: 17327605
[TBL] [Abstract][Full Text] [Related]
8. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Clark PE
Eur Urol; 2009 Jun; 55(6):1343-4. PubMed ID: 19201523
[No Abstract] [Full Text] [Related]
10. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
[TBL] [Abstract][Full Text] [Related]
11. Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.
Goebel S; Kehlen A; Bluemke K; Altermann W; Schlaf G; Fischer K; Fornara P; Wullich B; Wach S; Taubert H
Cancer Immunol Immunother; 2017 May; 66(5):565-571. PubMed ID: 28184970
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.
Ohlmann CH
Eur Urol; 2010 Feb; 57(2):325-6. PubMed ID: 19136198
[No Abstract] [Full Text] [Related]
13. High-dose interleukin-2 in metastatic renal cell carcinoma.
Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
[No Abstract] [Full Text] [Related]
14. HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis.
Maat W; Haasnoot GW; Claas FH; Schalij-Delfos NE; Schreuder GM; Jager MJ
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):3-6. PubMed ID: 16384937
[TBL] [Abstract][Full Text] [Related]
15. Expression and regulation of non-classical HLA-G in renal cell carcinoma.
Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B
Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274
[TBL] [Abstract][Full Text] [Related]
16. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
[TBL] [Abstract][Full Text] [Related]
17. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Bellmunt J; Ribas A
Eur Urol; 2009 Jun; 55(6):1342-3. PubMed ID: 19201525
[No Abstract] [Full Text] [Related]
18. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.
Kawai Y; Sakano S; Korenaga Y; Eguchi S; Naito K
Eur Urol; 2007 Oct; 52(4):1147-55. PubMed ID: 17287073
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.
Bukowski RM
Cancer; 2009 May; 115(10 Suppl):2273-81. PubMed ID: 19402065
[TBL] [Abstract][Full Text] [Related]
20. HLA class-I and class-II allele frequencies and two-locus haplotypes in Melanesians of Vanuatu and New Caledonia.
Maitland K; Bunce M; Harding RM; Barnardo MC; Clegg JB; Welsh K; Bowden DK; Williams TN
Tissue Antigens; 2004 Dec; 64(6):678-86. PubMed ID: 15546341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
